All of the following describes schizotypal personality disorder except,

A. Criminality. Criminal behavior is more characteristic of antisocial personality disorder (ASPD) rather than histrionic personality disorder (HPD). Individuals with ASPD display persistent disregard for social norms, often engaging in deception, aggression, and illegal activities. In contrast, those with HPD focus on gaining attention through dramatic and emotionally expressive behavior, not criminal acts.

B. Dramatic. Individuals with HPD exhibit excessive emotionality and attention-seeking behaviors, often overreacting to minor situations. Their interactions tend to be theatrical, exaggerated, and highly expressive, driven by a deep need for validation. This dramatic presentation can make their emotions seem intense but superficial, affecting personal and professional relationships.

C. Center of attention. A key feature of HPD is the constant desire to be the center of attention, leading to excessive efforts to draw focus in social settings. They may use flirtation, provocative behavior, or exaggerated stories to remain the focal point. If attention shifts away, they may become distressed or act impulsively to regain it, often without considering long-term consequences.

D. Emotionally shallow. Despite their expressive and intense emotional displays, individuals with HPD often lack emotional depth and sincerity. Their emotions can rapidly shift and may seem inconsistent or exaggerated, making it difficult to form genuine, long-lasting relationships. This superficiality often stems from their reliance on external validation rather than internal emotional awareness.

A. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, which has a higher risk of extrapyramidal symptoms (EPS) but a lower risk of metabolic syndrome compared to second-generation antipsychotics.

B. Aripiprazole (Abilify) is a second-generation (atypical) antipsychotic with a lower risk of metabolic side effects. It has a partial dopamine agonist mechanism, which makes it less likely to cause weight gain, dyslipidemia, or glucose intolerance.

C. Clozapine (Clozaril) has the highest risk of metabolic syndrome among antipsychotics. It is associated with significant weight gain, hyperglycemia, dyslipidemia, and an increased risk of diabetes. Regular metabolic monitoring (weight, blood glucose, lipids) is essential for patients taking clozapine.

D. Lurasidone (Latuda) is a second-generation antipsychotic with a lower metabolic risk compared to other atypical antipsychotics. It is generally considered weight-neutral and has minimal effects on glucose and lipid metabolism.